India Globalization Capital Quarterly Loss Per Share $0.03 [Reuters]
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Reuters
India Globalization Capital Inc ::IGC REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2019.QUARTERLY LOSS PER SHARE $0.03.QUARTERLY REVENUE $1.8 MILLION.
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s PipelineAccesswire
- IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss TherapiesAccesswire
- IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1Accesswire
- IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE ChallengeAccesswire
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentBusiness Wire
IGC
Analyst Actions
- 9/3/24 - Ascendiant Capital
IGC
Sec Filings
- 11/12/24 - Form 10-Q
- 9/27/24 - Form 8-K
- 9/27/24 - Form 4
- IGC's page on the SEC website